Everolimus alters imatinib blood partition in favour of the erythrocyte.

Prenen, Hans; Guetens, Gunther; De Boeck, Gert; Highley, Martin; van Oosterom, Allan T; de Bruijn, Ernst A

Prenen, Hans; Guetens, Gunther; De Boeck, Gert; Highley, Martin; van Oosterom, Allan T; de Bruijn, Ernst A.

Affiliation

Prenen H; Laboratory for Experimental Oncology, Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University Leuven, Belgium. hans.prenen@uz.kuleuven.be

J Pharm Pharmacol ; 58(8): 1063-6, 2006 Aug.

Article in En | MEDLINE | ID: mdl-16872552

Subject(s)

Antineoplastic Agents/blood; Erythrocytes/metabolism; Immunosuppressive Agents/pharmacology; Piperazines/blood; Pyrimidines/blood; Sirolimus/analogs & derivatives; Benzamides; Drug Resistance, Neoplasm; Erythrocytes/drug effects; Everolimus; Gastrointestinal Stromal Tumors/metabolism; Humans; Imatinib Mesylate; In Vitro Techniques; Mass Spectrometry; Plasma/chemistry; Plasma/metabolism; Sirolimus/pharmacology; Stomach Neoplasms/metabolism

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Piperazines / Pyrimidines / Sirolimus / Erythrocytes / Immunosuppressive Agents / Antineoplastic Agents Limits: Humans Language: En Journal: J Pharm Pharmacol Year: 2006 Type: Article Affiliation country: Belgium

Search on Google

Add to My VHL

XML

PubMed Links